Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Regeneron Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has SARS-CoV-2-positive antigen or molecular diagnostic test (by validated SARS-CoV-2 antigen, RT-PCR, or other molecular diagnostic assay, using an appropriate sample such as NP, nasal, oropharyngeal \[OP\], or saliva) ≤72 hours prior to randomization and no alternative explanation for current clinical condition. A historical record of positive result from test conducted ≤72 hours prior to randomization is acceptable.
Has symptoms consistent with COVID-19, as determined by investigator, with onset ≤10 days before randomization
Hospitalized for ≤72 hours with at least 1 of the following at randomization; patients meeting more than one criterion will be categorized in the most severely affected category:
1. Cohort 1A: With COVID-19 symptoms but not requiring supplemental oxygen
2. Cohort 1: Maintains O2 saturation \>93% on low-flow oxygen as defined in the protocol
3. Cohort 2: High-intensity oxygen therapy without mechanical ventilation as defined in the protocol
4. Cohort 3: On mechanical ventilation
You may not be if
Phase 1 Only: Patients maintaining O2 saturation \>94% on room air
In the opinion of the investigator, unlikely to survive for \>48 hours from screening
